INS and type 2 diabetes mellitus: Interestingly, the MOBILE randomized control trial completed in a racial/ethnically and socioeconomically diverse patient population with T2DM on basal insulin showed that 6 months after discontinuing continuous glucose monitoring, its benefit on glycemic outcomes including time-in-range was largely lost [14].